Research programme: spinal muscular atrophy therapeutics - PTC Therapeutics

Drug Profile

Research programme: spinal muscular atrophy therapeutics - PTC Therapeutics

Latest Information Update: 18 Aug 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator PTC Therapeutics
  • Developer PTC Therapeutics; Roche; Spinal Muscular Atrophy Foundation
  • Class Small molecules
  • Mechanism of Action Survival of motor neuron 1 protein stimulants; Survival of motor neuron 2 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Spinal muscular atrophy

Most Recent Events

  • 18 Aug 2014 Pharmacodynamics data from in vitro and preclinical studies in Spinal muscular atrophy released by PTC Therapeutics and Roche
  • 12 Aug 2013 Preclinical trials in Spinal muscular atrophy in USA (PO)
  • 15 Dec 2011 Early research in Spinal muscular atrophy in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top